Increased incidence of bladder cancer with metabolically unhealthy status: analysis from the National Health Checkup database in Korea

Jong Wook Kim1, Sun Tae Ahn1, Mi Mi Oh1, Du Geon Moon1, Jun Cheon3, Kyungdo Han2, Seon Mee Kim3 & Hong Seok Park1*

We assessed the association between metabolic health status and the incidence of bladder cancer using nationally representative data from the National Health Insurance System and National Health Checkups (NHC) databases in South Korea. Data for 11,781,768 men who participated in the NHC between 2009 and 2012 were analysed. The normal-weight and physically obese categories were defined as body mass indexes (BMI) < 25 and ≥ 25 kg/m², respectively. Metabolically obese was defined as the presence of ≥ 3 components of metabolic syndrome. The participants were stratified into metabolically healthy, normal-weight (MHNW); metabolically obese, normal-weight (MONW); metabolically healthy, obese (MHO); metabolically obese, obese (MOO). Multivariate-adjusted Cox regression analysis was conducted to examine the association between metabolic health status and the incidence of bladder cancer. The study participants included 17,777 men newly registered with bladder cancer. Analysis according to metabolic health status classification revealed a higher multivariable-adjusted hazard ratio in the MOO, MONW group than in the MHO group (1.307 [95% CI: 1.258–1.358], 1.183 [95% CI: 1.137–1.231] and 1.066 [95% CI: 1.017–1.119], respectively; hazard ratios given relative to MHNW group). We found an association between metabolic health status and the incidence of bladder cancer, with an increasing risk according to the number of metabolic health status components.

Obesity is associated with diabetes, cardiovascular disease, several types of cancers, and a decreased life expectancy1. However, not all obese patients are at high risk for these diseases, indicating that there are ‘healthy obese’ individuals among obese patients. Recently, metabolically healthy obese (MHO) patients have been defined as those with increased body weight and body mass index (BMI) but no or few metabolic conditions such as diabetes, hypertension, and dyslipidaemia2,3. Conversely, the metabolically obese, normal-weight (MONW) patients, defined as those with a normal body weight but various metabolic diseases, have a high risk for various diseases and a high mortality rate4–8.

The existing studies on cancer epidemiology are mostly on the effects of obesity or metabolic syndrome on cancer incidence; however, this subject has not been sufficiently explored with regard to the metabolic health status.

Bladder cancer is one of the ten most common cancers. Each year, there are 380,000 new patients, among whom 150,000 die9,10. There have been studies on the relationship between obesity and bladder cancer11,12 and between metabolic syndrome and bladder cancer13,14, but no study has been conducted on the relationship between bladder cancer and metabolic health. It is unknown whether bladder cancer risk is different for metabolically healthy obese and metabolically obese normal weight men.

1Department of Urology, Korea University College of Medicine, Seoul, Republic of Korea. 2Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 3Department of Family Medicine, Korea University College of Medicine, Seoul, Republic of Korea. *email: dr4you@korea.ac.kr
In this study, we aimed to assess the association between metabolic health status and the incidence of bladder cancer using nationally representative data of the Korean population.

**Materials and Methods**

**Data source and study population.** In South Korea, the National Health Insurance System (NHIS) established in 2000 covers about 98% of the citizens (about 50 million in 2014)\(^\text{15}\). All insurance members and dependents are asked to undergo a free biannual health check-up as part of the NHIS. In 2013, about 68% of members received a full health check-up\(^\text{16}\), making it possible to obtain information on population-wide disease status\(^\text{17}\).

In the present study, sex, birth date, past history, medication history, socioeconomic data, body size phenotypes, and diagnostic codes based on the International Statistical Classification of Diseases and related health problems 10th revision, Clinical Modification (ICD-10-CM) were retrieved.

Data from a total of 11,781,768 men who participated in the National Health Checkups (NHC) program between January 2009 and December 2012 were analysed. Body size phenotypes were classified according to BMI, which was calculated from measured height and weight, and the presence or absence of metabolic syndrome according to the results of the NHC\(^\text{17}\).

Since patients that are diagnosed with cancer, cardiovascular disease, cerebrovascular disease, and rare disease are entitled to economic benefits from the Korean government\(^\text{18}\), almost all physician-diagnosed cancer patients are registered in the central database\(^\text{19}\). Bladder cancer was coded as C67 in the ICD-10-CM. A flowchart for the selection of the study participants is shown in Fig. 1.

**Definition of metabolic health status.** ‘Physically obese’ was categorized according to the World Health Organization’s (WHO) definition of obesity for Asians. The study population was divided into the (physically) obese (BMI ≥ 25 kg/m\(^2\)) and normal weight (BMI < 25 kg/m\(^2\)) groups\(^\text{20,21}\).

‘Metabolically obese’ was defined according to the modified criteria by the National Cholesterol Education Program-Adult Treatment Panel III. This criteria requires the presence of three or more of the following components: triglyceride level ≥ 150 mg/dL, high-density lipoprotein (HDL) cholesterol level < 40 mg/dL, fasting glucose level ≥ 100 mg/dL (or taking anti-diabetic medications), blood pressure (BP) ≥ 130/85 mmHg (or taking antihypertensive drugs), or waist circumference (WC) ≥ 90 cm, according to the Asian-specific WC cut-off\(^\text{22,23}\).

Each metabolic disease was defined based on the health check-up data. Systolic and diastolic BP measurements were taken in a seated position after 5 minutes of rest. Blood sampling for glucose and lipid profile was performed after overnight fasting\(^\text{19}\). Smoking, drinking, exercise, and socio-economic status data were self-reported.

Subjects were stratified into four groups based on their metabolic health status: metabolically healthy, normal-weight (MHNW); MONW; MHO; and metabolically obese, obese (MOO).

**Statistical analyses.** Data were analysed using SAS version 9.3 (SAS Institute, Cary, NC, USA). All values in this study were expressed as the mean ± standard deviations (SD) and proportions for continuous and categorical variables. A multivariate-adjusted Cox regression analysis was performed to assess the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between bladder cancer and metabolic health status. Age, smoking status, alcohol consumption, exercise, and economic status were adjusted. A P-values below 0.001 was considered significant.

**Ethical statement.** The present study protocol was reviewed and approved by the Institutional Review Board (IRB) of the Korea University Guro Hospital. The requirement for informed consent from the participants was waived by the IRB (No. 2017GR0219). The present study was performed in accordance with relevant guidelines and regulations. To protect the individuals’ privacy, each patient’s identification number was anonymized.

**Results**

**Baseline characteristics of the study population.** This study included men who received an NHC between 2009 and 2012. For those who received an NHC two or more times in the above period, only the results from the first check-up were included. In addition, 12,471 subjects who were previously diagnosed with bladder cancer were excluded. In the end, of the 25,103,585 possible check-up visits, 11,781,768 were enrolled in this
The median follow-up duration was 5.4 years. Hypertension: blood pressure ≥ 130/85 mmHg or taking antihypertensive medications. Diabetes: fasting glucose level ≥ 100 mg/dL or taking anti-diabetic medications. Dyslipidaemia: triglyceride level ≥ 150 mg/dL, high-density lipoprotein cholesterol level < 40 mg/dL. Metabolic health status: healthy weight; MH, metabolically healthy; MO, metabolically obese; BMI, body mass index; WC, waist circumference; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; GFR, glomerular filtration rate.

After dividing the groups according to BMI levels, multivariable (age, smoking, drinking, exercise)-adjusted HRs for the incidence of bladder cancer were 1.071–1.142, 1.12 (95% CI: 1.087–1.154), 1.178 (95% CI: 1.144–1.213), and 1.199 (95% CI: 1.162–1.237), respectively (Table 2).

Within these two groups revealed significant differences in age distribution, smoking, drinking, exercise, diabetes, hypertension, BMI, WC, BP, glucose level, and lipid profile (P < 0.001).

The two groups were then divided into four groups according to metabolic health status. The MH group included 6,169,451 men (52.4%), the MONW group included 1,228,925 (10.4%), the MHO group included 2,313,991 (19.6%), and the MOO group included 2,069,401 (17.6%). Between these groups, there were significant differences in age, WC, BP, fasting glucose level, and lipid profile. In the MONW group, 30.7% had incident diabetes, 58.2% had incident hypertension, and 46.3% had incident dyslipidaemia. In the MHO group, 3.9% had incident diabetes, 19.7% had incident hypertension, and 11.8% had incident dyslipidaemia.

The mean age was highest in the MONW group, followed by the MOO, MHNW, and MHO groups. In terms of lifestyle, the MHNW group had the highest smoking rate, while the MOO group showed the highest rate of frequent drinking (more than once per week). The rate of regular exercise (once per week) was lowest in the MONW group.

Table 1 summarizes the general characteristics of the study population and subgroups.

### Incidence and risk of bladder cancer according to obesity and metabolic health status.

Within the 5.4 ± 1.1 years of follow-up, 17,777 of the patients were newly-diagnosed and registered with bladder cancer.

After dividing the groups according to BMI levels, multivariable (age, smoking, drinking, exercise)-adjusted HR for the incidence of bladder cancer was the lowest in the group with a BMI < 18.5 kg/m² and highest for those with a BMI between 25–30 kg/m². When the subjects were divided according to WC, hypertension, diabetes, high triglyceride, and low high-density lipoprotein, the HRs were 1.217 (95% CI: 1.178–1.256), 1.106 (95% CI: 1.071–1.142), 1.12 (95% CI: 1.087–1.154), 1.178 (95% CI: 1.144–1.213), and 1.199 (95% CI: 1.162–1.237), respectively (Table 2).

Of the 3,298,326 metabolically obese patients, 7,626 were newly-diagnosed with bladder cancer, resulting in an HR of 1.224 (95% CI: 1.188–1.261). As the number of metabolic factors increased, the HR also increased significantly (Fig. 2).
After the subjects were stratified into the MHNW, MONW, MHO, and MOO groups, multivariable-adjusted HRs were 1.183 (95% CI: 1.137–1.231) in the MONW group, 1.066 (95% CI: 1.017–1.119) in the MHO group, and 1.307 (95% CI: 1.258–1.358) in the MOO group, showing a higher HR in the MONW group than in the MHO group. In additional secondary analysis excluding the first 12 months, the results remain unchanged. (Table 3)

| Event Duration (person-years) | IR (per 1000 person-years) | Multivariable-adjusted HR * (95% CI) |
|-------------------------------|-----------------------------|------------------------------------|
| BMI, kg/m² <18.5              | 280,457                     | 573                                | 1,451,988.41 | 0.39463 | 0.968 (0.889–1.055) |
| 18.5–23                       | 3,970,603                   | 6,052                              | 21,405,151.08 | 0.28274 | 1 (ref.) |
| 23–25                         | 3,147,316                   | 4,914                              | 17,099,066.95 | 0.28738 | 1.085 (1.045–1.127) |
| 25–30                         | 3,934,367                   | 5,825                              | 21,279,792.75 | 0.27373 | 1.156 (1.115–1.199) |
| >30                           | 449,025                     | 413                                | 2,374,578.85 | 0.17393 | 1.146 (1.037–1.267) |
| WC, cm <90                    | 9,155,550                   | 12,411                             | 49,532,933.98 | 0.25056 | 1 (ref.) |
| ≥90                           | 2,626,218                   | 5,366                              | 14,077,644.07 | 0.38117 | 1.217 (1.178–1.256) |
| HTN No                        | 5,942,325                   | 5,647                              | 32,204,726.79 | 0.17535 | 1 (ref.) |
| Yes                           | 5,839,443                   | 12,130                             | 31,405,851.26 | 0.38623 | 1.085 (1.045–1.127) |
| DM No                         | 7,487,275                   | 8,976                              | 40,615,361.53 | 0.221 | 1 (ref.) |
| Yes                           | 4,294,493                   | 8,801                              | 22,995,216.52 | 0.38273 | 1.12 (1.087–1.154) |
| High TG No                    | 6,848,357                   | 9,372                              | 36,955,739   | 0.2536 | 1 (ref.) |
| Yes                           | 4,933,411                   | 8,405                              | 26,654,839.05 | 0.31533 | 1.178 (1.144–1.213) |
| Low HDL No                    | 9,180,364                   | 11,784                             | 49,671,734.08 | 0.23724 | 1 (ref.) |
| Yes                           | 2,601,404                   | 5,993                              | 13,938,843.97 | 0.42995 | 1.199 (1.162–1.237) |
| MO No                         | 8,483,442                   | 10,151                             | 45,964,233.99 | 0.22085 | 1 (ref.) |
| Yes                           | 3,298,326                   | 7,626                              | 17,646,344.06 | 0.43216 | 1.224 (1.188–1.261) |

Table 2. Association between Metabolic Parameters and Incidence Rate of Bladder Cancer. Abbreviations: IR, incidence rate; HR, hazard ratio; CI, confidence interval; BMI, body mass index; WC, waist circumference; HTN, hypertension; DM, diabetes mellitus; TG, triglyceride; LDL, low-density lipoprotein; MO, metabolically obese. *Adjusted for age, smoking, alcohol drinking, exercise, and income.

Figure 2. Kaplan-Meier estimates of survival curves for the time to incident bladder cancer, stratified by metabolic health status. The median follow-up duration was 5.4 years. The subjects were divided into six groups according to the number of components of metabolic health status (log-rank test, P < 0.001).

After the subjects were stratified into the MHNW, MONW, MHO, and MOO groups, multivariable-adjusted HRs were 1.183 (95% CI: 1.137–1.231) in the MONW group, 1.066 (95% CI: 1.017–1.119) in the MHO group, and 1.307 (95% CI: 1.258–1.358) in the MOO group, showing a higher HR in the MONW group than in the MHO group. In additional secondary analysis excluding the first 12 months, the results remain unchanged. (Table 3)
Among patients 65 years of age and older, multivariable HR of the MHO group was 0.923 (95% CI: 0.789–1.079), lower than that of the MHNW group. Among nonsmokers, multivariable-adjusted HRs were 1.186 (95% CI: 1.127–1.248) in the MONW group, 1.081 (95% CI: 1.019–1.148) in the MHO group, and 1.33 (95% CI: 1.269–1.395) in the MOO group, showing a higher HR in the MONW group than in the MHO group (Table 4).

Discussion
In this study, we confirmed a significant correlation between metabolic health status and the incidence of bladder cancer.

First, after we corrected for age and various other factors, we found the HR for the incidence of bladder cancer was highest in the MOO group, followed by the MONW, MHO, and MHNW groups. Second, the HR increased with an increasing number of factors related to metabolic health status.

Although BMI is generally used to define obesity, this measure cannot assess the distribution of fat and muscle. Therefore, obesity determined on BMI is not enough to judge its effect on cancer. There are many studies on obesity and cancer, but the results of these studies need to be interpreted carefully.

More important than BMI is the presence of metabolic disease. In this study, the HR of the MONW patients was higher than that of the MHO patients, suggesting that metabolic health status is a more important factor than BMI-based obesity in terms of bladder cancer.

The definition of metabolic health has not yet been established. In general, good metabolic health is defined as the absence of metabolic disorders such as type 2 diabetes, dyslipidaemia, and hypertension.24 We defined the metabolically obese as having ≥3 components of metabolic syndrome according to the definition proposed by Meigs et al.,7 which is the same as the definition of metabolic syndrome in the NCEP-ATP III. Metabolic obesity is regarded as a combination of central obesity, diabetes, hypertension, and dyslipidaemia, and each of these components can affect the development of bladder cancer.

According to the prospective cohort study by Haggstrom et al., involving 580,000 subjects, metabolic syndrome significantly increased the risk of bladder cancer in men (relative risk [RR] = 1.10; 95% CI: 1.01–1.18).

| group     | n  | Events | Duration | IR (per 1000 person-years) | HR (95% C.I.)               | Multivariable-adjusted * |
|-----------|----|--------|----------|---------------------------|----------------------------|--------------------------|
| Total     | MHNW | 6,169,451 | 7,958 | 33,409,087.62 | 0.2382 | 1 (ref.) | 1 (ref.) |
|           | MONW | 1,228,925 | 3,581 | 6,547,118.82 | 0.54696 | 1.187 (1.14–1.235) | 1.183 (1.137–1.231) |
|           | MHO  | 2,313,991 | 2,193 | 12,555,146.37 | 0.17467 | 1.024 (0.976–1.073) | 1.066 (1.017–1.119) |
|           | MOO  | 2,064,401 | 4,045 | 11,099,225.24 | 0.36444 | 1.271 (1.224–1.32) | 1.307 (1.258–1.358) |

Table 3. Association between Metabolic Status and Incidence of Bladder Cancer. Abbreviations: IR, incidence rate; HR, hazard ratio; CI, confidence interval; MHNW, metabolically healthy, normal-weight; MONW, metabolically obese, normal-weight; MHO, metabolically healthy, obese; MOO, metabolically obese, obese. *Adjusted for age, smoking, alcohol drinking, exercise, and income.

| group     | n  | Events | Duration | IR (per 1000 person-years) | HR (95% C.I.)               | Multivariable-adjusted * |
|-----------|----|--------|----------|---------------------------|----------------------------|--------------------------|
| Age <65 y | MHNW | 5,483,115 | 3,477 | 29,793,347.87 | 0.1167 | 1 (ref.) | 1 (ref.) |
|           | MONW | 909,118 | 1,358 | 4,890,175.63 | 0.2777 | 1.24 (1.173,1.31) | 1.271 (1.203,1.343) |
|           | MHO  | 2,170,690 | 1,287 | 11,775,367.33 | 0.1093 | 1.023 (0.959,1.09) | 1.067 (1.001,1.138) |
|           | MOO  | 1,788,785 | 1,984 | 9,605,029.14 | 0.20656 | 1.237 (1.161,1.318) | 1.222 (1.147,1.302) |
| Age ≥65 y | MHNW | 686,336 | 4,481 | 3,615,739.75 | 1.2393 | 1 (ref.) | 1 (ref.) |
|           | MONW | 319,807 | 2,223 | 1,656,943.19 | 1.34163 | 1.233 (1.088,1.398) | 1.23 (1.083,1.394) |
|           | MHO  | 143,301 | 906 | 779,779.04 | 1.16187 | 0.917 (0.785,1.072) | 0.923 (0.789,1.079) |
|           | MOO  | 280,616 | 2,061 | 1,494,196.1 | 1.37954 | 1.245 (1.089,1.422) | 1.238 (1.083,1.414) |
| Nonsmokers | MHNW | 3,306,101 | 4,481 | 179,404,256 | 0.25662 | 1 (ref.) | 1 (ref.) |
|           | MONW | 714,813 | 2,233 | 382,457,052 | 0.58342 | 1.202 (1.143,1.265) | 1.186 (1.127,1.248) |
|           | MHO  | 1,318,425 | 1,453 | 718,476,363 | 0.20223 | 1.084 (1.021,1.15) | 1.081 (1.019,1.148) |
|           | MOO  | 1,201,607 | 2,744 | 647,537,99 | 0.42376 | 1.343 (1.283,1.41) | 1.33 (1.269,1.395) |

Table 4. Subgroup analysis according to age and smoking. Abbreviations: IR, incidence rate; HR, hazard ratio; CI, confidence interval; MHNW, metabolically healthy, normal-weight; MONW, metabolically obese, normal-weight; MHO, metabolically healthy, obese; MOO, metabolically obese, obese. *Adjusted for age, smoking, alcohol drinking, exercise, and income.
In a meta-analysis, Esposito et al.\textsuperscript{13} also reported that metabolic syndrome was associated with an increased risk of bladder cancer in men. However, since metabolic syndrome is a combination of various diseases, some people argue that analysing it as a sole condition is not appropriate\textsuperscript{25}.

To date, there is no definite conclusion regarding the relationship between obesity and bladder cancer. Holick et al.\textsuperscript{11} and Haggstrom et al.\textsuperscript{14} reported no correlation between obesity and bladder cancer. Additionally, the International Agency for Research on Cancer reported that although colon, stomach, liver, gallbladder, pancreas, kidney cancer had a relationship with obesity, there was no evidence that bladder cancer was associated with obesity\textsuperscript{26}.

However, Koebnick et al.\textsuperscript{12} claimed that obesity increased the risk of bladder cancer and Ferro et al.\textsuperscript{27} revealed that BMI plays a role in the recurrence and progression of non-muscle-invasive bladder cancer. In the Asian population, a recent study\textsuperscript{28} showed that the incidence of bladder cancer was higher in the overweight and obese population.

In one study conducted in Asia, Xu et al.\textsuperscript{29} reported that diabetes and hypertriglyceridemia but not obesity and hypertension increased the risk of bladder cancer; as the number of metabolic syndrome components increased, so did the risk of bladder cancer.

Abdominal obesity has been proposed to better reflect obesity-related health risk than obesity based on BMI\textsuperscript{30}. Montella et al.\textsuperscript{31} reported that abdominal obesity increased the risk of bladder cancer by 63% (95% CI: 1.22–2.19). Cantiello et al.\textsuperscript{32} revealed that visceral obesity was a predictor and adverse pathological feature in bladder cancer. In this study, a metabolically obese status had a more significant influence on bladder cancer incidence than physical obesity.

There are recent studies on the relationship between systemic inflammation markers and cancer outcomes\textsuperscript{33}. Systemic inflammatory status is also suggested as a possible predictor of diabetes, obesity, and cancer. Unfortunately, we could not check the inflammatory status in this study.

One strength of this study was the nationwide large-scale sample size, which allows the results to be generally applied to Korean or East Asian populations. A considerable amount of the Korean population receives NHCs. As most cancer patients receive C codes through national registration, this study has high reliability compared to that of other cohort studies. Even though the differences in HR were not large, all of them were statistically significant due to the large number of subjects.

This study has several limitations. First, the data lack detailed information on bladder cancer; therefore, research on the cancer stage and histological differences was not possible. Only the incidence could be analysed and relapse or mortality rates could not be assessed. Second, for the same reason, we could not perform subgroup analysis for smoking, exercise, and alcohol intake. As smoking is one of the strongest known risk factors for bladder cancer, variable smoking status or pack-years data is important for studying bladder cancer. Additionally, since this was a huge dataset, we could not perform a quantitative analysis. Third, there was a risk of selection bias because health check-ups are attended mostly by healthy people. Fourth, the groups could change with time, however, we could not perform a time-dependent analysis. We checked and stratified the groups only at the time of enrollment.

Despite these limitations, to our knowledge, our study is the first large-scale cohort study to show the relationship between metabolic health status and bladder cancer. In the future, extensive research will be necessary along with more detailed clinical patient data.

Conclusion
This large-scale cohort study showed a significant relationship between metabolic health status and the incidence of bladder cancer. The risk increased with the number of metabolic health components. The hazard ratio for the incidence of bladder cancer was higher in MONW patients than in MHO patients.

Received: 18 September 2019; Accepted: 2 April 2020;
Published: xx xx xxxx

Published online: 15 April 2020

1. Mokdad, A. H. et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. \textit{JAMA} \textbf{289}, 76–79 (2003).
2. Phillips, C. M. Metabolically healthy obesity: definitions, determinants and clinical implications. \textit{Rev. Endocr. Metab. Disord.} \textbf{14}, 219–227 (2013).
3. Ruderman, N. B., Schneider, S. H. & Berchtold, P. The “metabolically-obese,” normal-weight individual. \textit{Am. J. Clin. Nutr.} \textbf{34}, 1617–1621 (1981).
4. Conus, F. et al. Metabolic and behavioral characteristics of metabolically obese but normal-weight women. \textit{Am. J. Clin. Endocrinol. Metab.} \textbf{89}, 5013–5020 (2004).
5. Dvorak, R. V., DeNino, W. F., Ades, P. A. & Poehlman, E. T. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. \textit{Diabetes} \textbf{48}, 2210–2214 (1999).
6. Hyun, Y. J. et al. Atherogenicity of LDL and unfavorable adipokine profile in metabolically obese, normal-weight woman. \textit{Obesity (Silver Spring)} \textbf{16}, 784–789 (2008).
7. Meigs, J. B. et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. \textit{J. Clin. Endocrinol. Metab.} \textbf{91}, 2906–2912 (2006).
8. Stefan, N., Schick, F. & Haring, H. U. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. \textit{Cell Metab.} \textbf{26}, 292–300 (2017).
9. Chavan, S., Bray, F., Lortet-Tieulent, J., Goodman, M. & Jemal, A. International variations in bladder cancer incidence and mortality. \textit{Eur. Urol.} \textbf{66}, 59–73 (2014).
10. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. \textit{Int. J. Cancer} \textbf{127}, 2893–2917 (2010).
11. Holick, C. N., Giovannucci, E. L., Stampfer, M. J. & Michaud, D. S. Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. \textit{Int. J. Cancer} \textbf{120}, 140–146 (2007).
12. Koebnick, C. et al. Body mass index, physical activity, and bladder cancer in a large prospective study. \textit{Cancer Epidemiol. Biomarkers Prev.} \textbf{17}, 1214–1221 (2008).
13. Esposito, K., Capuano, A. & Giugliano, D. Metabolic syndrome and cancer: holistic or reductionist? Endocrine 45, 362–364 (2014).
14. Haghtalab, C. et al. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (MeCan). Int. J. Cancer 128, 1890–1896 (2011).
15. Kim, J. A. & Yoon, S. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J. Korean Med. Sci. 32, 718–724 (2017).
16. Lee, Y. H., Han, K., Ko, S. H., Ko, K. S. & Lee, K. U. Data analytic process of a nationwide population-based study using national health information database established by national health insurance service. Diabetes Metab. J. 40, 79–82 (2016).
17. Yoo, H. J. et al. Influences of body size phenotype on the incidence of gestational diabetes needing prescription; analysis by Korea National Health Insurance (KNHI) claims and the National Health Screening Examination (NHSE) database. Metabolism 65, 1259–1266 (2016).
18. Kim, T. et al. Epidemiology of Moyamoya Disease in Korea: based on National Health Insurance Service Data. J. Korean Neuropsychiat. Soc. 57, 390–395 (2015).
19. Choi, J. B. et al. The impact of diabetes on the risk of prostate cancer development according to body mass index: a 10-year nationwide cohort study. J. Cancer 7, 2061–2066 (2016).
20. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ. Tech. Rep. Ser. 894, i–xiii, 1–253 (2000).
21. Lee, H. et al. Atrial fibrillation risk in metabolically healthy obesity: A nationwide population-based study. Int. J. Cardiol. 240, 221–227 (2017).
22. Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009).
23. Choi, J. Y. et al. Characteristics of metabolically obese, normal-weight women differ by menopause status: the Fourth Korea National Health and Nutrition Examination Survey. Menopause 20, 85–93 (2013).
24. Bühler, M. Are metabolically healthy obese individuals really healthy? Eur. J. Endocrinol. 171, R209–219 (2014).
25. Wallner, L., P. P. et al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int. 107, 929–935 (2011).
26. Lauby-Secretan, B. et al. Body Fatness and Cancer–Viewpoint of the IARC Working Group. N. Engl. J. Med. 375, 794–798 (2016).
27. Ferro, M. et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. 37, 507–514, (2019).
28. Rezaei, F., Tabatabaei, H. R., Rahmanian, V., Mirahmadizadeh, A. & Hassanipour, S. The Correlation Between Bladder Cancer and Obesity, Overweight, Physical Inactivity, and Tobacco Use: An Ecological Study in Asian Countries. Annals of global health 85, (2019).
29. Xu, S. et al. The association between metabolic syndrome and the risk of urethelial carcinoma of the bladder: a case-control study in China. World J. Surg. Oncol. 13, 236 (2015).
30. Matsushita, Y. et al. How can waist circumference predict the body composition? Diabetol. Metab. Syndr. 6, 11 (2014).
31. Montella, M. et al. Metabolic syndrome and the risk of urethelial carcinoma of the bladder: a case-control study. BMC Cancer 15, 720 (2015).
32. Cantillo, F. et al. Visceral obesity predicts adverse pathological features in urethelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study. World J. Urol. 32, 559–564 (2014).
33. Cantillo, F. et al. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. European urology oncology 1, 403–410 (2018).

Acknowledgements
This research used National Health Insurance Service (NHIS) data (NHIS-2017–1–099) provided by the NHIS. This research was supported by a Research Foundation Grant funded by the Korean Urological Association (2018-KUA-001) and Korea University Grant (K1924991).

Author contributions
K.J.W., H.K.D. and P.H.S. conceived the study. K.J.W. and H.K.D. collected the data, performed the statistical analysis. K.J.W. wrote the main manuscript text. A.S.T., O.M.M., M.D.G., C.J., K.S.M. helped to conceive the study and draft the manuscript. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to H.S.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020